Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide

• Status: Terminated
• Trial end date: 2013-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains unchanged.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: Carbamazepine; Etiracetam; Lacosamide; Levetiracetam; Piracetam

Criteria

Inclusion Criteria:

• Male subject with diagnosis of Epilepsy with Partial-Onset Seizures

• Subject only taking Levetiracetam in combination with Carbamazepine as adjunctive treatment for Epilepsy

Exclusion Criteria:

• Subject is taking another Anti-Epileptic Drug (AED) than Carbamazepine (CBZ) and Levetiracetam (LEV)

• Subject is taking lipid lowering agents

• Subject is taking enzyme inducers